Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial
| Autor: | M.D. Michaelson, Michael A. Tortorici, T. de La Motte Rouge, Paul Bycott, Robert J. Motzer, Antonella Ingrosso, Andrea L. Harzstark, B. I. Rini, Viktor Gruenwald, Sinil Kim, Glenn Liu |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Second-line therapy biology business.industry VEGF receptors urologic and male genital diseases medicine.disease Vascular endothelial growth factor Axitinib stomatognathic diseases chemistry.chemical_compound chemistry Renal cell carcinoma Internal medicine medicine biology.protein Overall survival In patient business Receptor medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 29:4547-4547 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 4547 Background: Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1–3. Axitinib in patients (pts) with cytokine-refractory mRCC (Rixe et a... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|